Probiotic stool secretory immunoglobulin A modulation in children with gastroenteritis: a randomized clinical trial
| Autor: | Stephen B. Freedman, Ken J. Farion, Jianling Xie, Katrina F. Hurley, Naveen Poonai, David Schnadower, Kathene C. Johnson-Henry, Suzanne Schuh, Linda Chui, Xiao-Li Pang, Bonita E. Lee, Yaron Finkelstein, Philip M. Sherman, Serge Gouin, Rachael G. Horne, Sarah Williamson-Urquhart |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Immunoglobulin A Emergency Medical Services medicine.medical_specialty Medicine (miscellaneous) immunoglobulin A Placebo Gastroenterology law.invention Immunomodulation AcademicSubjects/MED00160 Feces 03 medical and health sciences Probiotic AcademicSubjects/MED00060 0302 clinical medicine Lactobacillus rhamnosus Randomized controlled trial law Internal medicine Infectious Diseases and Immunity Clinical endpoint medicine Humans Nutrition and Dietetics biology Lacticaseibacillus rhamnosus business.industry Probiotics Infant clinical trial biology.organism_classification Lactobacillus helveticus 3. Good health Regimen Original Research Communications 030104 developmental biology pediatric Specimen collection Acute Disease Immunoglobulin A Secretory biology.protein Female 030211 gastroenterology & hepatology business gastroenteritis probiotic |
| Zdroj: | The American Journal of Clinical Nutrition Paediatrics Publications |
| ISSN: | 1938-3207 0002-9165 |
| Popis: | Background We previously conducted the Probiotic Regimen for Outpatient Gastroenteritis Utility of Treatment (PROGUT) study, which identified no improvements in children with acute gastroenteritis (AGE) administered a probiotic. However, the aforementioned study did not evaluate immunomodulatory benefits. Objectives The object of this study was to determine if stool secretory immunoglobulin A (sIgA) concentrations in children with AGE increase more among participants administered a Lactobacillus rhamnosus/helveticus probiotic compared with those administered placebo. Methods This a priori planned multicenter, randomized, double-blinded, placebo-controlled ancillary study enrolled children presenting for emergency care who received a 5-d probiotic or placebo course. Participants submitted stool specimens on days 0, 5, and 28. The primary endpoint was the change in stool sIgA concentrations on day 5 compared with baseline. Results A total of 133 (n = 66 probiotic, 67 placebo) of 886 PROGUT participants (15.0%) provided all 3 specimens. Median stool sIgA concentrations did not differ between the probiotic and placebo groups at any of the study time points: day 0 median (IQR): 1999 (768, 4071) compared with 2198 (702, 5278) (P = 0.27, Cohen's d = 0.17); day 5: 2505 (1111, 5310) compared with 3207 (982, 7080) (P = 0.19, Cohen's d = 0.16); and day 28: 1377 (697, 2248) compared with 1779 (660, 3977) (P = 0.27, Cohen's d = 0.19), respectively. When comparing measured sIgA concentrations between days 0 and 5, we found no treatment allocation effects [β: −0.24 (−0.65, 0.18); P = 0.26] or interaction between treatment and specimen collection day [β: −0.003 (−0.09, 0.09); P = 0.95]. Although stool sIgA decreased between day 5 and day 28 within both groups (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|